The illusion of simplicity: Diagnostic inconsistencies within the STEMI paradigm.

J ElectrocardiolJun 10, 2026 (epub)
Case ReportCardiology

William H Frick, Stephen W Smith

✦ AI-curated · Sources linked

Case in brief

A 65-year-old male presented with acute chest pain and an ECG indicative of left anterior descending coronary artery involvement. However, the ECG did not meet the millimeter criteria for STEMI, leading to a misclassification as NSTEMI and delayed management. Coronary angiography revealed a total thrombotic occlusion of the LAD 15 hours post-presentation.

Diagnostic / clinical pearl

Clinicians should be cautious of relying solely on millimeter-based STEMI criteria, as they may overlook significant coronary occlusions, particularly in cases involving the left anterior descending artery.

Why it matters

This case highlights the need for a shift from the STEMI paradigm to the Occlusion Myocardial Infarction paradigm to enhance diagnostic accuracy and improve patient outcomes.

Source

PubMed · PMID 42287922

Published in J Electrocardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.